Evaluation of TGFβ1 receptor transcript levels showed significantly reduced TGFβR2 expression, which probably hamper tumor suppressive effect of TGFβ1 in CML patients. Here, TGFBR2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.